LAURUSLABS

Laurus Labs benefits from favourable industry dynamics, including increasing demand for generic drugs, active pharmaceutical ingredients (APIs), and contract research and manufacturing services. The company’s diversified product portfolio and focus on innovation position it well to capture growth opportunities both domestically and internationally. As a mid-cap entity, Laurus Labs offers a compelling blend of growth potential and relative stability compared to smaller peers, making it an attractive candidate for momentum-based strategies that seek to balance risk and reward.